• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型AKT抑制剂Hu7691大鼠口服给药后的安全性和毒理学研究

Safety and Toxicology Study of Hu7691, a Novel AKT Inhibitor, following Oral Administration in Rats.

作者信息

Gai Renhua, Chen Chao, Zhang Wei, Ma Jian, Wang Xiaomeng, Chi Xiaoqing, Li Guangxing

机构信息

College of Veterinary Medicine, Heilongjiang Key Laboratory for Animal and Comparative Medicine, Northeast Agricultural University, Harbin 150030, China.

Center for Drug Safety Evaluation and Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

出版信息

Toxics. 2023 Oct 26;11(11):880. doi: 10.3390/toxics11110880.

DOI:10.3390/toxics11110880
PMID:37999532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10674281/
Abstract

Hu7691 represents a novel Pan-Akt kinase inhibitor, demonstrating excellent selectivity towards non-AGC kinase families and pronounced inhibitory effects on the proliferation of multiple tumor cell lines. However, there is currently a notable absence of in vivo toxicological research evidence concerning Hu7691. This study represents the first investigation into the 14-day repeated-dose toxicity of Hu7691 in male and female Sprague Dawley (SD) rats. Male rats were administered daily doses of 12.5, 50, 100, and 150 mg/kg/day, while female rats received doses of 12.5, 25, 50, and 75 mg/kg/day for 14 consecutive days. Hematological assessments, organ weights, and histopathological examinations revealed corresponding alterations, suggesting potential target organs for toxicity including the spleen, thymus, and gastrointestinal tract. It is worth noting that the test substance may also impact the liver, kidneys, heart, and ovaries. The No Observed Effect Level (NOAEL) was determined to be no greater than 12.5 mg/kg/day. Based on the observed gender-related toxicity differences in preliminary trials, it is recommended that the high dose reference dose for male animals in formal experiments should not be less than 100 mg/kg/day, while for female animals, it should be less than 50 mg/kg/day.

摘要

Hu7691是一种新型的泛Akt激酶抑制剂,对非AGC激酶家族表现出优异的选择性,并对多种肿瘤细胞系的增殖具有显著的抑制作用。然而,目前关于Hu7691的体内毒理学研究证据明显不足。本研究首次对Hu7691在雄性和雌性Sprague Dawley(SD)大鼠中的14天重复给药毒性进行了调查。雄性大鼠每日剂量为12.5、50、100和150 mg/kg/天,而雌性大鼠连续14天接受剂量为12.5、25、50和75 mg/kg/天的给药。血液学评估、器官重量和组织病理学检查显示了相应的变化,表明潜在的毒性靶器官包括脾脏、胸腺和胃肠道。值得注意的是,受试物质也可能影响肝脏、肾脏、心脏和卵巢。未观察到有害作用水平(NOAEL)被确定为不超过12.5 mg/kg/天。基于在初步试验中观察到的性别相关毒性差异,建议在正式实验中雄性动物的高剂量参考剂量不应低于100 mg/kg/天,而雌性动物的高剂量参考剂量应低于50 mg/kg/天。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b1/10674281/5b3a54a74e12/toxics-11-00880-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b1/10674281/d370c07add72/toxics-11-00880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b1/10674281/6c967bd60796/toxics-11-00880-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b1/10674281/5b3a54a74e12/toxics-11-00880-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b1/10674281/d370c07add72/toxics-11-00880-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b1/10674281/6c967bd60796/toxics-11-00880-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90b1/10674281/5b3a54a74e12/toxics-11-00880-g003.jpg

相似文献

1
Safety and Toxicology Study of Hu7691, a Novel AKT Inhibitor, following Oral Administration in Rats.新型AKT抑制剂Hu7691大鼠口服给药后的安全性和毒理学研究
Toxics. 2023 Oct 26;11(11):880. doi: 10.3390/toxics11110880.
2
3
NTP Toxicology and Carcinogenesis Studies of p-Nitrobenzoic Acid (CAS No. 62-23-7) in F344/N Rats and B6C3F1 Mice (Feed Studies).对硝基苯甲酸(CAS编号:62-23-7)在F344/N大鼠和B6C3F1小鼠中的NTP毒理学和致癌性研究(饲料研究)
Natl Toxicol Program Tech Rep Ser. 1994 Dec;442:1-306.
4
Toxicology and carcinogenesis studies of 3,3',4,4'-tetrachloroazobenzene (TCAB) (CAS No. 14047-09-7) in Harlan Sprague-Dawley rats and B6C3F1 mice (gavage studies).3,3',4,4'-四氯偶氮苯(TCAB)(化学物质登记号:14047-09-7)在哈兰斯普拉格-道利大鼠和B6C3F1小鼠中的毒理学和致癌性研究(灌胃研究)
Natl Toxicol Program Tech Rep Ser. 2010 Nov(558):1-206.
5
Comparative chronic toxicity and carcinogenicity of acrylonitrile by drinking water and oral intubation to Spartan Sprague-Dawley rats.饮用水和经口插管给予丙烯腈对斯帕坦斯普拉格-道利大鼠的慢性毒性和致癌性比较
Toxicol Lett. 2002 Jun 24;132(3):197-219. doi: 10.1016/s0378-4274(02)00073-5.
6
NTP Technical Report on the Toxicity Studies of 3,3',4,4'-Tetrachloroazoxybenzene (CAS No. 21232-47-3) Administered by Gavage to F344/N Rats and B6C3F1 Mice.美国国家毒理学计划关于经口给予F344/N大鼠和B6C3F1小鼠3,3',4,4'-四氯偶氮苯(化学物质登记号:21232-47-3)的毒性研究技术报告
Toxic Rep Ser. 1998 Nov;66:1-G4.
7
Toxicology and carcinogenesis studies of methylene blue trihydrate (Cas No. 7220-79-3) in F344/N rats and B6C3F1 mice (gavage studies).三水合亚甲蓝(化学物质登记号:7220-79-3)在F344/N大鼠和B6C3F1小鼠中的毒理学和致癌性研究(灌胃研究)
Natl Toxicol Program Tech Rep Ser. 2008 May(540):1-224.
8
AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells.AKT抑制剂Hu7691诱导神经母细胞瘤细胞分化。
Acta Pharm Sin B. 2023 Apr;13(4):1522-1536. doi: 10.1016/j.apsb.2023.01.024. Epub 2023 Feb 4.
9
NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).4,4'-硫代双(6-叔丁基间甲酚)(CAS编号:96-69-5)在F344/N大鼠和B6C3F1小鼠中的NTP毒理学和致癌性研究(饲料研究)
Natl Toxicol Program Tech Rep Ser. 1994 Dec;435:1-288.
10
NTP Technical Report on the Toxicity Studies of 3,3',4,4'-Tetrachloroazobenzene (CAS No. 14047-09-7) Administered by Gavage to F344/N Rats and B6C3F1 Mice.NTP关于经口给予F344/N大鼠和B6C3F1小鼠3,3',4,4'-四氯偶氮苯(CAS编号14047-09-7)的毒性研究技术报告。
Toxic Rep Ser. 1998 Nov;65:1-F6.

本文引用的文献

1
AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells.AKT抑制剂Hu7691诱导神经母细胞瘤细胞分化。
Acta Pharm Sin B. 2023 Apr;13(4):1522-1536. doi: 10.1016/j.apsb.2023.01.024. Epub 2023 Feb 4.
2
Inhibition of methotrexate induced toxicity in the adult rat spleen by adalimumab.阿达木单抗对甲氨蝶呤诱导的成年大鼠脾脏毒性的抑制作用。
Drug Chem Toxicol. 2023 Mar;46(2):323-329. doi: 10.1080/01480545.2022.2029880. Epub 2022 Jan 20.
3
Targeting PI3K/Akt signal transduction for cancer therapy.针对 PI3K/Akt 信号转导通路的癌症治疗策略。
Signal Transduct Target Ther. 2021 Dec 16;6(1):425. doi: 10.1038/s41392-021-00828-5.
4
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.PI3K/Akt/mTOR信号通路抑制剂在前列腺癌化学预防和干预中的作用
Pharmaceutics. 2021 Aug 3;13(8):1195. doi: 10.3390/pharmaceutics13081195.
5
Discovery of -((3,4)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1-pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity.发现 -((3,4)-4-(3,4-二氟苯基)哌啶-3-基)-2-氟-4-(1-甲基-1-吡唑-5-基)苯甲酰胺 (Hu7691),一种有效的和选择性的 Akt 抑制剂,可降低皮肤毒性。
J Med Chem. 2021 Aug 26;64(16):12163-12180. doi: 10.1021/acs.jmedchem.1c00815. Epub 2021 Aug 10.
6
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.TAS-117(一种变构 Akt 抑制剂)治疗携 PI3K/AKT 基因突变的晚期实体瘤的 II 期研究
Invest New Drugs. 2021 Oct;39(5):1366-1374. doi: 10.1007/s10637-021-01085-7. Epub 2021 Mar 15.
7
Akt Pathway Inhibitors. Akt 通路抑制剂。
Curr Top Med Chem. 2020;20(10):883-900. doi: 10.2174/1568026620666200224101808.
8
Nonproliferative and Proliferative Lesions of the Rat and Mouse Hematolymphoid System.大鼠和小鼠血液淋巴系统的非增殖性和增殖性病变
Toxicol Pathol. 2019 Aug;47(6):665-783. doi: 10.1177/0192623319867053.
9
PI3K-AKT-mTOR and NFκB Pathways in Ovarian Cancer: Implications for Targeted Therapeutics.卵巢癌中的PI3K-AKT-mTOR和NFκB信号通路:对靶向治疗的启示
Cancers (Basel). 2019 Jul 5;11(7):949. doi: 10.3390/cancers11070949.
10
Reference values for selected hematological, biochemical and physiological parameters of Sprague-Dawley rats at the Animal House, Faculty of Medicine, University of Colombo, Sri Lanka.斯里兰卡科伦坡大学医学院动物房Sprague-Dawley大鼠选定血液学、生化和生理参数的参考值。
Animal Model Exp Med. 2018 Nov 21;1(4):250-254. doi: 10.1002/ame2.12041. eCollection 2018 Dec.